TMDX Stock Risk & Deep Value Analysis
Transmedics Group Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About TMDX Stock
We analyzed Transmedics Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TMDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is TMDX Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for TMDX?
- ⚠
Slower than expected adoption of OCS Kidney or other OCS platforms.
- ⚠
Significant adverse events or recalls associated with OCS technology.
- ⚠
Emergence of a highly competitive or disruptive alternative organ preservation technology.
- ⚠
Negative changes in healthcare reimbursement policies impacting OCS profitability.
Unlock TMDX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Transmedics Group Inc (TMDX) Do?
Market Cap
$4.58B
Sector
Healthcare
Industry
Medical Devices
Employees
728
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit Transmedics Group Inc WebsiteIs TMDX Stock Undervalued?
Unlock the full AI analysis for TMDX
Get the complete DVR score, risk analysis, and more
Is TMDX Financially Healthy?
P/E Ratio
67.84
Does TMDX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
TMDX's moat is highly durable due to the significant regulatory hurdles for Class III medical devices, the extensive and proprietary clinical data required for multi-organ approval, and the entrenched relationships with transplant centers. Replicating this ecosystem would require substantial capital, time, and clinical success.
Moat Erosion Risks
- •A breakthrough competitor technology that is significantly cheaper, simpler, or more effective.
- •Changes in regulatory landscape that ease market entry for competitors or invalidate existing approvals.
- •Major safety or efficacy concerns emerging from long-term OCS use.
TMDX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive TMDX Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Expected late-March 2026) showcasing continued revenue growth and margin expansion.
- •Updates on accelerated OCS Kidney adoption rates across new transplant centers.
- •Announcements of new international market entries for OCS Heart, Lung, or Liver.
Medium-Term (6-18 months)
- •Potential clinical trial commencement or progress updates for OCS Pancreas or other new organs.
- •Expansion of OCS reimbursement coverage or favorable policy changes in key markets.
- •Formation of new strategic partnerships with major healthcare systems or logistics providers.
Long-Term (18+ months)
- •OCS becoming the undisputed global standard of care for multi-organ transplantation, displacing cold static storage.
- •Development and commercialization of next-generation OCS platforms with enhanced capabilities or new applications.
- •Expansion into organ repair or regeneration alongside preservation.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TMDX?
- ✓
Acceleration in OCS utilization rates, especially for Kidney and Liver programs.
- ✓
Updates on new regulatory approvals or significant market expansion into new geographies.
- ✓
Maintenance or expansion of gross and operating margins, indicating operational efficiency as it scales.
Bull Case Analysis
See what could go right with Premium
Compare TMDX to Similar Stocks
See how Transmedics Group Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TMDX (Transmedics Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
